<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04218604</url>
  </required_header>
  <id_info>
    <org_study_id>Ablation-by-LAW</org_study_id>
    <nct_id>NCT04218604</nct_id>
  </id_info>
  <brief_title>The Ablate-by-LAW Study</brief_title>
  <official_title>Feasibility and Efficacy of Tailoring Ablation Index to Left Atrial Wall Thickness During Atrial Fibrillation Ablation: The Ablate By-LAW Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Medico Teknon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart and Diabetes Center North Rhine-Westphalia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliero, Universitaria Pisana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heart Center Leipzig - University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Puerta del Mar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro Medico Teknon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Of all the determinants of lesion creation during atrial fibrillation (AF) ablation, left
      atrial wall thickness (LAWT), as measured with multi-detector cardiac tomography (MDCT) is
      one key element that has been evaluated in some retrospective analyses but is not yet used
      per protocol to modulate the radiofrequency delivery. Adapting ablation index (AI) to LAWT
      would be very useful in standardising the ablation procedure with parameters fitted to every
      patient, enabling the development of a personalized approach that will both: i) increase
      efficacy by performing transmural lesions to prevent the formation of conduction gaps in the
      initial lesion set, and ii) increase safety by preventing excessive RF delivery on thin wall
      areas related to procedural complications, such as cardiac perforation or atrio-esophageal
      fistula. The investigators sought to evaluate the feasibility, safety, efficacy and
      reproducibility of guiding AF ablation procedures with the integrated MDCT-derived LAWT
      information.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arrhythmia-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>1-year atrial arrhythmia-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute procedural outcomes</measure>
    <time_frame>1 day</time_frame>
    <description>Procedure times</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-procedural complications</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>REDO outcomes</measure>
    <time_frame>2 years</time_frame>
    <description>Mean LAWT at late reconnection sites</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">281</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Personalized AF ablation using MDCT-derived LAWT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-procedural MDCT images will be analysed in Teknon Medical Center (core-lab), using ADAS-3D™ (Galgo Medical, Barcelona, Spain) to obtain 3D atrial wall thickness maps that will be introduced into CARTO® navigation system (Biosense Webster, Diamond Bar, California, US). PVI will be performed point-by-point, aiming to complete a RF circle around the PV ostia (nephroid shape) on the 3D geometry using a ThermoCool® SmartTouch® 3.5-mm irrigated tip contact force-sensing RF ablation catheter (Biosense Webster, Inc.). AI targets will be defined by LAWT on the thickness color map, as follows: Thickness &lt; 1 mm (red): 300; 1-2 mm (yellow): 350; 2-3 mm (green): 400; 3-4 mm (blue): 450; &gt; 4 mm (purple): 500. The recommended power settings to reach these AI values will be, in general, 35 W for the posterior wall and 40 W for the anterior wall. Wherever local AWT is &gt; 3 mm (green and blue colors), an increased RF power (50 W) will be permitted.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Personalized atrial fibrillation ablation</intervention_name>
    <description>Atrial fibrillation (AF) ablation adapting the ablation index (AI) target in a point-by-point manner, according the local left atrial wall thickness (LAWT), as measured by multidetector cardiac tomography (MDCT)</description>
    <arm_group_label>Personalized AF ablation using MDCT-derived LAWT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years.

          -  Indication for paroxysmal atrial fibrillation ablation.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Age &lt; 18 years.

          -  Pregnancy.

          -  Previous AF ablation procedure (REDO).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antonio Berruezo, MD, PhD</last_name>
    <phone>(+34) 932 290 62 51</phone>
    <email>antonio.berruezo@quironsalud.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beatriz Jauregui, MD</last_name>
    <phone>(+34) 932 290 62 51</phone>
    <email>beatriz.jauregui@quironsalud.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Peter Zimetbaum, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Saman Nazarian, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum Nordrhein-Westfalen</name>
      <address>
        <city>Bad Oeynhausen</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Philipp Sommer, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heart Center Leipzig University Hospital</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Gerhard Hindricks, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Giulio Zucchelli, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teknon Medical Center</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Antonio Berruezo, MD, PhD</last_name>
      <phone>(+34) 932 290 62 51</phone>
      <email>antonio.berruezo@quironsalud.es</email>
    </contact>
    <contact_backup>
      <last_name>Beatriz Jauregui, MD</last_name>
      <phone>(+34) 932 290 62 51</phone>
      <email>beatriz.jauregui@quironsalud.es</email>
    </contact_backup>
    <investigator>
      <last_name>Beatriz Jauregui, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Soto-Iglesias, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Berruezo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Puerta del Mar University Hospital</name>
      <address>
        <city>Cadiz</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Juan Fernandez-Armenta, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castellá M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Alexandru Popescu B, Schotten U, Van Putte B, Vardas P. 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. Rev Esp Cardiol (Engl Ed). 2017 Jan;70(1):50. doi: 10.1016/j.rec.2016.11.033. English, Spanish. Erratum in: Rev Esp Cardiol (Engl Ed). 2017 Nov;70(11):1031.</citation>
    <PMID>28038729</PMID>
  </reference>
  <reference>
    <citation>Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar JG, Badhwar V, Brugada J, Camm J, Chen PS, Chen SA, Chung MK, Nielsen JC, Curtis AB, Davies DW, Day JD, d'Avila A, de Groot NMSN, Di Biase L, Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G, Gerstenfeld EP, Haines DE, Haissaguerre M, Helm RH, Hylek E, Jackman WM, Jalife J, Kalman JM, Kautzner J, Kottkamp H, Kuck KH, Kumagai K, Lee R, Lewalter T, Lindsay BD, Macle L, Mansour M, Marchlinski FE, Michaud GF, Nakagawa H, Natale A, Nattel S, Okumura K, Packer D, Pokushalov E, Reynolds MR, Sanders P, Scanavacca M, Schilling R, Tondo C, Tsao HM, Verma A, Wilber DJ, Yamane T. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. J Arrhythm. 2017 Oct;33(5):369-409. doi: 10.1016/j.joa.2017.08.001. Epub 2017 Sep 15.</citation>
    <PMID>29021841</PMID>
  </reference>
  <reference>
    <citation>Ouyang F, Tilz R, Chun J, Schmidt B, Wissner E, Zerm T, Neven K, Köktürk B, Konstantinidou M, Metzner A, Fuernkranz A, Kuck KH. Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up. Circulation. 2010 Dec 7;122(23):2368-77. doi: 10.1161/CIRCULATIONAHA.110.946806. Epub 2010 Nov 22.</citation>
    <PMID>21098450</PMID>
  </reference>
  <reference>
    <citation>Cappato R, Negroni S, Pecora D, Bentivegna S, Lupo PP, Carolei A, Esposito C, Furlanello F, De Ambroggi L. Prospective assessment of late conduction recurrence across radiofrequency lesions producing electrical disconnection at the pulmonary vein ostium in patients with atrial fibrillation. Circulation. 2003 Sep 30;108(13):1599-604. Epub 2003 Sep 8.</citation>
    <PMID>12963643</PMID>
  </reference>
  <reference>
    <citation>Kuck KH, Hoffmann BA, Ernst S, Wegscheider K, Treszl A, Metzner A, Eckardt L, Lewalter T, Breithardt G, Willems S; Gap-AF–AFNET 1 Investigators*. Impact of Complete Versus Incomplete Circumferential Lines Around the Pulmonary Veins During Catheter Ablation of Paroxysmal Atrial Fibrillation: Results From the Gap-Atrial Fibrillation-German Atrial Fibrillation Competence Network 1 Trial. Circ Arrhythm Electrophysiol. 2016 Jan;9(1):e003337. doi: 10.1161/CIRCEP.115.003337.</citation>
    <PMID>26763226</PMID>
  </reference>
  <reference>
    <citation>Ikeda A, Nakagawa H, Lambert H, Shah DC, Fonck E, Yulzari A, Sharma T, Pitha JV, Lazzara R, Jackman WM. Relationship between catheter contact force and radiofrequency lesion size and incidence of steam pop in the beating canine heart: electrogram amplitude, impedance, and electrode temperature are poor predictors of electrode-tissue contact force and lesion size. Circ Arrhythm Electrophysiol. 2014 Dec;7(6):1174-80. doi: 10.1161/CIRCEP.113.001094. Epub 2014 Nov 7.</citation>
    <PMID>25381331</PMID>
  </reference>
  <reference>
    <citation>Thiagalingam A, D'Avila A, Foley L, Guerrero JL, Lambert H, Leo G, Ruskin JN, Reddy VY. Importance of catheter contact force during irrigated radiofrequency ablation: evaluation in a porcine ex vivo model using a force-sensing catheter. J Cardiovasc Electrophysiol. 2010 Jul;21(7):806-11. doi: 10.1111/j.1540-8167.2009.01693.x. Epub 2010 Feb 1.</citation>
    <PMID>20132400</PMID>
  </reference>
  <reference>
    <citation>Barkagan M, Rottmann M, Leshem E, Shen C, Buxton AE, Anter E. Effect of Baseline Impedance on Ablation Lesion Dimensions: A Multimodality Concept Validation From Physics to Clinical Experience. Circ Arrhythm Electrophysiol. 2018 Oct;11(10):e006690. doi: 10.1161/CIRCEP.118.006690.</citation>
    <PMID>30354405</PMID>
  </reference>
  <reference>
    <citation>Reddy VY, Dukkipati SR, Neuzil P, Natale A, Albenque JP, Kautzner J, Shah D, Michaud G, Wharton M, Harari D, Mahapatra S, Lambert H, Mansour M. Randomized, Controlled Trial of the Safety and Effectiveness of a Contact Force-Sensing Irrigated Catheter for Ablation of Paroxysmal Atrial Fibrillation: Results of the TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation (TOCCASTAR) Study. Circulation. 2015 Sep 8;132(10):907-15. doi: 10.1161/CIRCULATIONAHA.114.014092. Epub 2015 Aug 10.</citation>
    <PMID>26260733</PMID>
  </reference>
  <reference>
    <citation>Shah DC, Lambert H, Nakagawa H, Langenkamp A, Aeby N, Leo G. Area under the real-time contact force curve (force-time integral) predicts radiofrequency lesion size in an in vitro contractile model. J Cardiovasc Electrophysiol. 2010 Sep;21(9):1038-43. doi: 10.1111/j.1540-8167.2010.01750.x.</citation>
    <PMID>20367658</PMID>
  </reference>
  <reference>
    <citation>De Potter T, Van Herendael H, Balasubramaniam R, Wright M, Agarwal SC, Sanders P, Khaykin Y, Latcu DG, Maury P, Pani A, Hayes J, Kalman J, Nery P, Duncan E. Safety and long-term effectiveness of paroxysmal atrial fibrillation ablation with a contact force-sensing catheter: real-world experience from a prospective, multicentre observational cohort registry. Europace. 2018 Nov 1;20(FI_3):f410-f418. doi: 10.1093/europace/eux290.</citation>
    <PMID>29315382</PMID>
  </reference>
  <reference>
    <citation>Ho SY, Cabrera JA, Tran VH, Farré J, Anderson RH, Sánchez-Quintana D. Architecture of the pulmonary veins: relevance to radiofrequency ablation. Heart. 2001 Sep;86(3):265-70.</citation>
    <PMID>11514476</PMID>
  </reference>
  <reference>
    <citation>Ho SY, Sánchez-Quintana D. The importance of atrial structure and fibers. Clin Anat. 2009 Jan;22(1):52-63. doi: 10.1002/ca.20634. Review.</citation>
    <PMID>18470938</PMID>
  </reference>
  <reference>
    <citation>Kistler PM, Ho SY, Rajappan K, Morper M, Harris S, Abrams D, Sporton SC, Schilling RJ. Electrophysiologic and anatomic characterization of sites resistant to electrical isolation during circumferential pulmonary vein ablation for atrial fibrillation: a prospective study. J Cardiovasc Electrophysiol. 2007 Dec;18(12):1282-8. Epub 2007 Oct 3.</citation>
    <PMID>17916142</PMID>
  </reference>
  <reference>
    <citation>Takahashi K, Okumura Y, Watanabe I, Nagashima K, Sonoda K, Sasaki N, Kogawa R, Iso K, Ohkubo K, Nakai T, Hirayama A. Relation Between Left Atrial Wall Thickness in Patients with Atrial Fibrillation and Intracardiac Electrogram Characteristics and ATP-Provoked Dormant Pulmonary Vein Conduction. J Cardiovasc Electrophysiol. 2015 Jun;26(6):597-605. doi: 10.1111/jce.12660. Epub 2015 May 1.</citation>
    <PMID>25777254</PMID>
  </reference>
  <reference>
    <citation>Suenari K, Nakano Y, Hirai Y, Ogi H, Oda N, Makita Y, Ueda S, Kajihara K, Tokuyama T, Motoda C, Fujiwara M, Chayama K, Kihara Y. Left atrial thickness under the catheter ablation lines in patients with paroxysmal atrial fibrillation: insights from 64-slice multidetector computed tomography. Heart Vessels. 2013 May;28(3):360-8. doi: 10.1007/s00380-012-0253-6. Epub 2012 Apr 22.</citation>
    <PMID>22526381</PMID>
  </reference>
  <reference>
    <citation>Nakamura K, Funabashi N, Uehara M, Ueda M, Murayama T, Takaoka H, Komuro I. Left atrial wall thickness in paroxysmal atrial fibrillation by multislice-CT is initial marker of structural remodeling and predictor of transition from paroxysmal to chronic form. Int J Cardiol. 2011 Apr 14;148(2):139-47. doi: 10.1016/j.ijcard.2009.10.032. Epub 2009 Nov 10.</citation>
    <PMID>19906452</PMID>
  </reference>
  <reference>
    <citation>Chikata A, Kato T, Sakagami S, Kato C, Saeki T, Kawai K, Takashima S, Murai H, Usui S, Furusho H, Kaneko S, Takamura M. Optimal Force-Time Integral for Pulmonary Vein Isolation According to Anatomical Wall Thickness Under the Ablation Line. J Am Heart Assoc. 2016 Mar 15;5(3):e003155. doi: 10.1161/JAHA.115.003155.</citation>
    <PMID>27068636</PMID>
  </reference>
  <reference>
    <citation>Sun JY, Yun CH, Mok GSP, Liu YH, Hung CL, Wu TH, Alaiti MA, Eck BL, Fares A, Bezerra HG. Left Atrium Wall-mapping Application for Wall Thickness Visualisation. Sci Rep. 2018 Mar 8;8(1):4169. doi: 10.1038/s41598-018-22089-z.</citation>
    <PMID>29520005</PMID>
  </reference>
  <reference>
    <citation>Bishop M, Rajani R, Plank G, Gaddum N, Carr-White G, Wright M, O'Neill M, Niederer S. Three-dimensional atrial wall thickness maps to inform catheter ablation procedures for atrial fibrillation. Europace. 2016 Mar;18(3):376-83. doi: 10.1093/europace/euv073. Epub 2015 Apr 4.</citation>
    <PMID>25842272</PMID>
  </reference>
  <reference>
    <citation>Schaeffer B, Willems S, Sultan A, Hoffmann BA, Lüker J, Schreiber D, Akbulak R, Moser J, Kuklik P, Steven D. Loss of Pace Capture on the Ablation Line During Pulmonary Vein Isolation versus &quot;Dormant Conduction&quot;: Is Adenosine Expendable? J Cardiovasc Electrophysiol. 2015 Oct;26(10):1075-80. doi: 10.1111/jce.12759. Epub 2015 Aug 29.</citation>
    <PMID>26183341</PMID>
  </reference>
  <results_reference>
    <citation>Das M, Loveday JJ, Wynn GJ, Gomes S, Saeed Y, Bonnett LJ, Waktare JEP, Todd DM, Hall MCS, Snowdon RL, Modi S, Gupta D. Ablation index, a novel marker of ablation lesion quality: prediction of pulmonary vein reconnection at repeat electrophysiology study and regional differences in target values. Europace. 2017 May 1;19(5):775-783. doi: 10.1093/europace/euw105.</citation>
    <PMID>27247002</PMID>
  </results_reference>
  <results_reference>
    <citation>Hussein A, Das M, Chaturvedi V, Asfour IK, Daryanani N, Morgan M, Ronayne C, Shaw M, Snowdon R, Gupta D. Prospective use of Ablation Index targets improves clinical outcomes following ablation for atrial fibrillation. J Cardiovasc Electrophysiol. 2017 Sep;28(9):1037-1047. doi: 10.1111/jce.13281. Epub 2017 Jul 26.</citation>
    <PMID>28639728</PMID>
  </results_reference>
  <results_reference>
    <citation>Taghji P, El Haddad M, Phlips T, Wolf M, Knecht S, Vandekerckhove Y, Tavernier R, Nakagawa H, Duytschaever M. Evaluation of a Strategy Aiming to Enclose the Pulmonary Veins With Contiguous and Optimized Radiofrequency Lesions in Paroxysmal Atrial Fibrillation: A Pilot Study. JACC Clin Electrophysiol. 2018 Jan;4(1):99-108. doi: 10.1016/j.jacep.2017.06.023. Epub 2017 Sep 27.</citation>
    <PMID>29600792</PMID>
  </results_reference>
  <results_reference>
    <citation>Inoue J, Skanes AC, Gula LJ, Drangova M. Effect of Left Atrial Wall Thickness on Radiofrequency Ablation Success. J Cardiovasc Electrophysiol. 2016 Nov;27(11):1298-1303. doi: 10.1111/jce.13065. Epub 2016 Sep 16.</citation>
    <PMID>27510229</PMID>
  </results_reference>
  <results_reference>
    <citation>Pambrun T, Combes S, Sousa P, Bloa ML, El Bouazzaoui R, Grand-Larrieu D, Thompson N, Martin R, Combes N, Boveda S, Haïssaguerre M, Albenque JP. Contact-force guided single-catheter approach for pulmonary vein isolation: Feasibility, outcomes, and cost-effectiveness. Heart Rhythm. 2017 Mar;14(3):331-338. doi: 10.1016/j.hrthm.2016.12.008. Epub 2016 Dec 7.</citation>
    <PMID>27940124</PMID>
  </results_reference>
  <results_reference>
    <citation>Steven D, Reddy VY, Inada K, Roberts-Thomson KC, Seiler J, Stevenson WG, Michaud GF. Loss of pace capture on the ablation line: a new marker for complete radiofrequency lesions to achieve pulmonary vein isolation. Heart Rhythm. 2010 Mar;7(3):323-30. doi: 10.1016/j.hrthm.2009.11.011. Epub 2009 Nov 12.</citation>
    <PMID>20185104</PMID>
  </results_reference>
  <results_reference>
    <citation>Eitel C, Hindricks G, Sommer P, Gaspar T, Kircher S, Wetzel U, Dagres N, Esato M, Bollmann A, Husser D, Hilbert S, Zaker-Shahrak R, Arya A, Piorkowski C. Circumferential pulmonary vein isolation and linear left atrial ablation as a single-catheter technique to achieve bidirectional conduction block: the pace-and-ablate approach. Heart Rhythm. 2010;7(2):157-64. doi: 10.1016/j.hrthm.2009.10.003. Epub 2009 Oct 12.</citation>
    <PMID>20036199</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 26, 2019</study_first_submitted>
  <study_first_submitted_qc>January 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2020</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro Medico Teknon</investigator_affiliation>
    <investigator_full_name>Antonio Berruezo, MD, PhD</investigator_full_name>
    <investigator_title>Principal investigator, cardiologist, cardiac electrophysiologist</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>catheter-based ablation</keyword>
  <keyword>radiofrequency ablation</keyword>
  <keyword>pulmonary vein isolation</keyword>
  <keyword>left atrial wall thickness</keyword>
  <keyword>multidetector cardiac tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 25, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT04218604/Prot_SAP_ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

